SequelSEC

AEON Biopharma, Inc. AEON

Pharmaceutical Preparations · CIK 0001837607 · Fiscal year ends 1231

Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$19.86M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

AEON Biopharma, Inc. (AEON) reported net income of -$54.62M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from AEON Biopharma, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

AEON Biopharma, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
RevenueUnavailable
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$19.86M
Net income-$54.62M
Research & development$7.18M
Weighted-average diluted sharesUnavailable
Pretax income-$54.62M
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$12.72M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

AEON Biopharma, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$3.43M
Total assets$5.91M
Current assets$3.99M
Total liabilities$21.27M
Current liabilities$7.34M
Total equity incl. NCI-$15.36M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$2.70M

Cash flow

AEON Biopharma, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$13.64M
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$8.63M
Net change in cash-$5.01M
Stock-based compensation$5.60M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$78.00K

Derived

AEON Biopharma, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio0.54x
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open AEON in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.